Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis

British Journal of Dermatology

Volumn 152, Issue 6, 2005, Pages 1173-1181

  Park, Chun Wook ^a   Lee, B H ^a   Han, H J ^a   Lee, C H ^a   Ahn, H K ^a  

^a Hallym University   (South Korea)

Author keywords

Atopic dermatitis; Eosinophils; Topical tacrolimus

Indexed keywords

CHEMOKINE RECEPTOR CCR3; EOTAXIN; INTERLEUKIN 5; MESSENGER RNA; RANTES; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; BLOOD LEVEL; BLOOD SAMPLING; CELL ACTIVATION; CELL COUNT; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EOSINOPHIL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; OINTMENT; PRIORITY JOURNAL; SKIN BIOPSY;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINES, CC; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; EOSINOPHILIA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-5; KOREA; LEUKOCYTE COUNT; MALE; OINTMENTS; RANTES; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN; TACROLIMUS;

EID: 21644464022     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06474.x     Document Type: Article

References (34)

1. Novak N, Bieber T, Leung DYM. Immune mechanism leading to atopic dermatitis. J Allergy Clin Immunol 2003; 112:128-395.
2. Meagher LJ, Wines NY, Cooper AJ. Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol 2002; 43:247-54.
3. Won CH, Seo PG, Park YM et al. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. J Dermatol Treat 2003; 14:1-5.
4. Reitamo S, Wollenberg A, Schopf E et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000; 136:999-1006.
5. Kang S, Lucky AW, Pariser D et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44 (Suppl.):58-64.
6. Cheer SM, Plosker GL. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2001; 2:389-402.
7. Shozo S, Yasuyuki H, Natuki S et al. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system (comparison with steroids). Int Immunopharmacol 2001; 1:1219-26.
8. Leiferman KM, Plager DA, Gleich GJ. Eosinophils and atopic dermatitis. In: Atopic Dermatitis (Bieber T, Leung DYM, eds). New York: Marcel Dekker, 2002; 327-55.
9. Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy 2004; 59:561-70.
10. Barnes PJ. Molecular mechanisms of corticosteroids in allergic diseases. Allergy 2001; 56:928-36.
11. Mori A, Kaminuma O, Suko M et al. Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Blood 1997; 89:2891-900.
12. Meagher LC, Cousin JM, Seckl JR et al. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996; 156:4422-8.
13. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; 92 (Suppl.):44-7.
14. Hanifin JM, Thurston M, Omoto M et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 2001; 10:11-18.
15. Beltrani VS, Boguneiwicz M. Atopic dermatitis. Dermatol Online J 2003; 9:1.
16. Novak N, Bieber T, Leung DYM. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003; 112 (Suppl.):128-39.
17. Hanifin JM. Atopic dermatitis: new therapeutic consideration. J Am Acad Dermatol 1991; 24:1097-101.
18. Kapp A. The role of eosinophils in the pathogenesis of atopic dermatitis: eosinophil granule proteins as markers of disease activity. Allergy 1993; 48:1-5.
19. Cheng JF, Ott NL, Peterson EA et al. Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration. J Allergy Clin Immunol 1997; 99:683-92.
20. Kristjansson S, Shimizu T, Strannegard IL, Wennergren G. Eosinophil cationic protein, myeloperoxidase and tryptase in children with asthma and atopic dermatitis. Pediatr Allergy Immunol 1994; 5:223-9.
21. Pucci N, Lombardi E, Novembre E et al. Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: correlation with disease activity. J Allergy Clin Immunol 2000; 105:353-7.
22. Ott NL, Gleich GJ, Peterson EA et al. Assessment of eosinophil and neutrophil participation in atopic dermatitis: comparison with the IgE-mediated late phase reaction. J Allergy Clin Immunol 1994; 94:120-8.
23. Simon HU. Eosinophil apoptosis-pathophysiologic and therapeutic implications. Allergy 2000; 55:910-15.
24. Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev 1999; 51:213-340.
25. Rankin SM, Conroy DM, Williams TJ. Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today 2000; 6:20-7.
26. Hossny E, Aboul-Magd M, Bakr S. Increased plasma eotaxin in atopic dermatitis and acute urticaria Ln infants and children. Allergy 2001; 56:996-1002.
27. Morita E, Kameyoshi Y, Hiragun T et al. The C-C chemokines, RANTES and eotaxin, in atopic dermatitis. Allergy 2001; 56:194-5.
28. Trautmann A, Akdis M, Klunker S et al. Role of apoptosis in atopic dermatitis. Int Arch Allergy Immunol 2001; 124:230-2.
29. Yawalkar N, Uguccioni M, Scharer J et al. Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J Invest Dermatol 1999; 113:43-8.
30. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine and FK506. Immunol Today 1992; 13:136-42.
31. Sigal NH, Dumont FJ. Cyclosporin A, FK506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992; 10:519-60.
32. Kagami S, Kakinuma T, Saeki H et al. Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis. Clin Exp Immunol 2003; 134:309-13.
33. Gerber BO, Zanni MP, Uguccioni M et al. Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol 1997; 7:836-43.
34. Kondo S, Yazawa H, Jimbow K. Reduction of serum interleukin-5 levels reflect clinical improvement in patients with atopic dermatitis. J Dermatol 2001; 28:237-43.